Published in J Clin Endocrinol Metab on July 21, 2011
Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A (2013) 5.88
Commensal bacteria make GPCR ligands that mimic human signalling molecules. Nature (2017) 2.01
International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev (2013) 1.60
Lipid stimulation of fatty acid sensors in the human duodenum: relationship with gastrointestinal hormones, BMI and diet. Int J Obes (Lond) (2016) 1.39
Mechanisms of gene regulation by fatty acids. Adv Nutr (2012) 1.11
Nutrient detection by incretin hormone secreting cells. Physiol Behav (2011) 1.06
Intestinal epithelial MyD88 is a sensor switching host metabolism towards obesity according to nutritional status. Nat Commun (2014) 1.05
Duodenal enteroendocrine I-cells contain mRNA transcripts encoding key endocannabinoid and fatty acid receptors. PLoS One (2012) 1.02
Intestinal GLP-1 and satiation: from man to rodents and back. Int J Obes (Lond) (2015) 1.00
Targeted lipidomics in Drosophila melanogaster identifies novel 2-monoacylglycerols and N-acyl amides. PLoS One (2013) 0.97
Gut chemosensing mechanisms. J Clin Invest (2015) 0.96
Physiology of incretins in health and disease. Rev Diabet Stud (2011) 0.95
Peripheral neural targets in obesity. Br J Pharmacol (2012) 0.92
Sensing of triacylglycerol in the gut: different mechanisms for fatty acids and 2-monoacylglycerol. J Physiol (2015) 0.91
Molecular mechanisms of incretin hormone secretion. Curr Opin Pharmacol (2013) 0.89
Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents. Diabetologia (2012) 0.89
Molecular targets related to inflammation and insulin resistance and potential interventions. J Biomed Biotechnol (2012) 0.88
Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis. Nat Rev Gastroenterol Hepatol (2012) 0.87
Mechanisms of exercise-induced hypoalgesia. J Pain (2014) 0.86
Analysis of ECs and related compounds in plasma: artifactual isomerization and ex vivo enzymatic generation of 2-MGs. J Lipid Res (2014) 0.86
Intestinal lipid-derived signals that sense dietary fat. J Clin Invest (2015) 0.85
G protein-coupled receptors as targets for anti-diabetic therapeutics. Nat Rev Drug Discov (2016) 0.83
Lipidomics profile of a NAPE-PLD KO mouse provides evidence of a broader role of this enzyme in lipid metabolism in the brain. Biochim Biophys Acta (2016) 0.82
Role of fatty acid transport protein 4 in oleic acid-induced glucagon-like peptide-1 secretion from murine intestinal L cells. Am J Physiol Endocrinol Metab (2012) 0.82
Vascular, but not luminal, activation of FFAR1 (GPR40) stimulates GLP-1 secretion from isolated perfused rat small intestine. Physiol Rep (2015) 0.81
Liver fatty acid-binding protein binds monoacylglycerol in vitro and in mouse liver cytosol. J Biol Chem (2013) 0.81
Stimulation of incretin secreting cells. Ther Adv Endocrinol Metab (2016) 0.81
Gastrointestinal hormonal responses on GPR119 activation in lean and diseased rodent models of type 2 diabetes. Int J Obes (Lond) (2014) 0.79
Lipid derivatives activate GPR119 and trigger GLP-1 secretion in primary murine L-cells. Peptides (2015) 0.79
Swim stress differentially affects limbic contents of 2-arachidonoylglycerol and 2-oleoylglycerol. Neuroscience (2011) 0.79
Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1. Int J Endocrinol (2015) 0.78
Stimulation of proglucagon gene expression by human GPR119 in enteroendocrine L-cell line GLUTag. Mol Endocrinol (2013) 0.78
Broad impact of deleting endogenous cannabinoid hydrolyzing enzymes and the CB1 cannabinoid receptor on the endogenous cannabinoid-related lipidome in eight regions of the mouse brain. Pharmacol Res (2016) 0.77
Intercellular Lipid Mediators and GPCR Drug Discovery. Biomol Ther (Seoul) (2013) 0.77
Where's my entourage? The curious case of 2-oleoylglycerol, 2-linolenoylglycerol, and 2-palmitoylglycerol. Pharmacol Res (2016) 0.77
The role of apolipoprotein A-IV in regulating glucagon-like peptide-1 secretion. Am J Physiol Gastrointest Liver Physiol (2015) 0.76
Dietary non-esterified oleic Acid decreases the jejunal levels of anorectic N-acylethanolamines. PLoS One (2014) 0.76
Female Mice are Resistant to Fabp1 Gene Ablation-Induced Alterations in Brain Endocannabinoid Levels. Lipids (2016) 0.76
Effect of Roux-en-Y gastric bypass surgery on intestinal Akkermansia muciniphila. World J Gastrointest Surg (2016) 0.76
A Lower Olfactory Capacity Is Related to Higher Circulating Concentrations of Endocannabinoid 2-Arachidonoylglycerol and Higher Body Mass Index in Women. PLoS One (2016) 0.75
Levels of bioactive lipids in cooking oils: olive oil is the richest source of oleoyl serine. J Basic Clin Physiol Pharmacol (2016) 0.75
Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling. Pharmacol Ther (2017) 0.75
Global deletion of MGL in mice delays lipid absorption and alters energy homeostasis and diet-induced obesity. J Lipid Res (2015) 0.75
Pharmacology and physiology of gastrointestinal enteroendocrine cells. Pharmacol Res Perspect (2015) 0.75
Interactions between gut microbes and host cells control gut barrier and metabolism. Int J Obes Suppl (2016) 0.75
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med (2006) 7.31
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ (2012) 5.57
Molecular mechanism of 7TM receptor activation--a global toggle switch model. Annu Rev Pharmacol Toxicol (2006) 3.33
Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) (2009) 3.15
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab (2006) 2.64
Ligand binding and micro-switches in 7TM receptor structures. Trends Pharmacol Sci (2009) 2.33
Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes (2007) 2.24
Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes (2007) 2.19
Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proc Natl Acad Sci U S A (2002) 2.19
Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab (2002) 2.18
The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes (2003) 2.16
Discriminating between cardiac and pulmonary dysfunction in the general population with dyspnea by plasma pro-B-type natriuretic peptide. J Am Coll Cardiol (2007) 2.13
International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev (2013) 2.11
Effect of a high-protein breakfast on the postprandial ghrelin response. Am J Clin Nutr (2006) 2.10
Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease. Kidney Int (2013) 2.08
Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab (2005) 2.04
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab (2007) 2.02
Glycemia and insulinemia in healthy subjects after lactose-equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. Am J Clin Nutr (2004) 2.01
Insulin resistance alters islet morphology in nondiabetic humans. Diabetes (2013) 2.01
Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes (2007) 1.96
Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept (2003) 1.91
Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab (2011) 1.90
Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. Am J Clin Nutr (2007) 1.86
Glucagon-like peptide 2 dose-dependently activates intestinal cell survival and proliferation in neonatal piglets. Endocrinology (2004) 1.78
The use of glycaemic index tables to predict glycaemic index of composite breakfast meals. Br J Nutr (2004) 1.74
Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes (2011) 1.74
Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest (2003) 1.73
Meal-stimulated glucagon release is associated with postprandial blood glucose level and does not interfere with glycemic control in children and adolescents with new-onset type 1 diabetes. J Clin Endocrinol Metab (2007) 1.72
Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci U S A (2007) 1.71
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab (2007) 1.70
Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes (2004) 1.68
Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes (2013) 1.66
Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes (2011) 1.63
Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes (2004) 1.62
Altered control of gastric acid secretion in gastrin-cholecystokinin double mutant mice. Gastroenterology (2004) 1.60
Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective. Biochem Biophys Res Commun (2002) 1.59
Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab (2011) 1.59
Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta (2008) 1.58
Small gallstones, preserved gallbladder motility, and fast crystallization are associated with pancreatitis. Hepatology (2005) 1.58
GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology (2006) 1.55
Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care (2007) 1.53
Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res (2003) 1.52
Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 study. Diabetes Care (2008) 1.50
Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion. Diabetes (2009) 1.50
Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects. J Clin Endocrinol Metab (2012) 1.49
Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing. Clin Chem (2002) 1.48
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs (2010) 1.46
The use of glycaemic index tables to predict glycaemic index of breakfast meals. Br J Nutr (2005) 1.45
Flash pulmonary edema in patients with renal artery stenosis--the Pickering Syndrome. Blood Press (2010) 1.45
Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab (2003) 1.45
Meals with similar energy densities but rich in protein, fat, carbohydrate, or alcohol have different effects on energy expenditure and substrate metabolism but not on appetite and energy intake. Am J Clin Nutr (2003) 1.44
The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care (2007) 1.44
The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes (2010) 1.43
[Antioxidants and health]. Ugeskr Laeger (2006) 1.39
Postprandial glucose, insulin, and incretin responses to grain products in healthy subjects. Am J Clin Nutr (2002) 1.38
[From where does the economic support to health research come?]. Ugeskr Laeger (2003) 1.38
Which of the n-3 FA should be called essential? Lipids (2003) 1.38
Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology (2006) 1.36
Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regul Pept (2004) 1.35
Diet- and colonization-dependent intestinal dysfunction predisposes to necrotizing enterocolitis in preterm pigs. Gastroenterology (2006) 1.34
GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab (2007) 1.33
The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol (2012) 1.32
GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1. Gastroenterology (2003) 1.31
A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin. Endocrinology (2012) 1.31
Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med (2004) 1.30
Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes (2005) 1.30
Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients. J Nutr (2011) 1.29
Antihyperglycemic effects of stevioside in type 2 diabetic subjects. Metabolism (2004) 1.27
The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clin Endocrinol (Oxf) (2009) 1.27
Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome. J Endocrinol (2010) 1.26
Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology (2011) 1.25
Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report. Diabetes Care (2009) 1.25
GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion. Mol Cell Endocrinol (2007) 1.24
Co-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes. Eur J Endocrinol (2007) 1.23
Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J Clin Endocrinol Metab (2009) 1.22
Pregnancy-induced rise in serum C-peptide concentrations in women with type 1 diabetes. Diabetes Care (2009) 1.22
The carboxyl terminus of human cytomegalovirus-encoded 7 transmembrane receptor US28 camouflages agonism by mediating constitutive endocytosis. J Biol Chem (2003) 1.20
GPR119 as a fat sensor. Trends Pharmacol Sci (2012) 1.20
Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes (2007) 1.20
Structural differences between rye and wheat breads but not total fiber content may explain the lower postprandial insulin response to rye bread. Am J Clin Nutr (2003) 1.19
Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care (2011) 1.17
Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans. Am J Physiol Endocrinol Metab (2007) 1.16
Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol (2007) 1.16
DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. Front Biosci (2008) 1.15
Gastric emptying, gastric secretion and enterogastrone response after administration of milk proteins or their peptide hydrolysates in humans. Eur J Nutr (2004) 1.15
The influence of nutrients, biliary-pancreatic secretions, and systemic trophic hormones on intestinal adaptation in a Roux-en-Y bypass model. J Pediatr Surg (2010) 1.15
Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion. Regul Pept (2007) 1.14
Effects of 1 and 3 g cinnamon on gastric emptying, satiety, and postprandial blood glucose, insulin, glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and ghrelin concentrations in healthy subjects. Am J Clin Nutr (2009) 1.13
Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol (2008) 1.13
Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes (2011) 1.12
Examining the effects of hyperglycemia on pancreatic endocrine function in humans: evidence for in vivo glucotoxicity. J Clin Endocrinol Metab (2012) 1.12